Marie Hogan
Overview
Explore the profile of Marie Hogan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chedid M, Chebib F, Dahlen E, Mueller T, Schnell T, Gay M, et al.
JMIR Med Inform
. 2024 May;
12:e50164.
PMID: 38717378
Background: Tolvaptan is the only US Food and Drug Administration-approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but it requires strict clinical monitoring due to...
2.
Abrams C, Jaffray J, Stillings A, Branchford B, Young G, Goldenberg N, et al.
Res Pract Thromb Haemost
. 2023 Nov;
6(7):e12793.
PMID: 38024326
Background: A rise in hospital-acquired venous thromboembolism (HA-VTE) in children has led to increased awareness regarding VTE prophylaxis and risk assessment. Despite no consensus exists regarding these practices in pediatrics....
3.
Natale P, Perrone R, Tong A, Harris T, Hannan E, Ju A, et al.
Clin Kidney J
. 2022 Feb;
15(3):407-416.
PMID: 35211300
Background: Pain is the highest prioritized patient-reported outcome in people with autosomal dominant polycystic kidney disease (ADPKD) but remains infrequently and inconsistently measured in clinical trials and poorly managed in...
4.
Natale P, Hannan E, Sautenet B, Ju A, Perrone R, Burnette E, et al.
PLoS One
. 2021 May;
16(5):e0252479.
PMID: 34043715
Pain is a common symptom in people with autosomal dominant polycystic kidney disease (ADPKD), but it is assessed and reported inconsistently in research, and the validity of the measures remain...
5.
Hogan M, Berger J
Vasc Med
. 2020 Mar;
25(2):160-173.
PMID: 32195628
Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening complication of heparin exposure. Here, we review the pathogenesis, incidence, diagnosis, and management of HIT. The first step in thwarting devastating complications...
6.
Hogan M, Geyer J, Bussel J
Am J Hematol
. 2019 Apr;
94(7):E196-E198.
PMID: 31012979
No abstract available.
7.
Nowak K, You Z, Gitomer B, Brosnahan G, Torres V, Chapman A, et al.
J Am Soc Nephrol
. 2017 Nov;
29(2):571-578.
PMID: 29118087
The association of overweight/obesity with disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) remains untested. We hypothesized that overweight/obesity associates with faster progression in early-stage ADPKD. Overall,...
8.
Lafayette R, Canetta P, Rovin B, Appel G, Novak J, Nath K, et al.
J Am Soc Nephrol
. 2016 Nov;
28(4):1306-1313.
PMID: 27821627
IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody-producing B...
9.
Dunne F, Avalos G, Durkan M, Mitchell Y, Gallacher T, Keenan M, et al.
Diabetes Care
. 2009 Jul;
32(7):1205-6.
PMID: 19564472
Objective: Prospective evaluation of pregnancy outcomes in pregestational diabetes along the Atlantic seaboard 2006-2007. Research Design And Methods: The Atlantic Diabetes in Pregnancy group, representing five antenatal centers in a...